GLP-1 drugs reduce CV events 24%, kidney events 36%, and mortality 51% in obese non-diabetic adults—largest study to date | Research

The takeaway

Target trial emulation of 280,338 adults with obesity (no diabetes) shows GLP-1 drugs reduced MACE 24% (HR 0.76), kidney events 36% (HR 0.64), mortality 51% (HR 0.49), depression 37%, suicidal ideation 58%, and substance use disorder 42% versus other AOMs.

51% lower mortality + 58% less suicidal ideation
In 280,338 non-diabetic adults with obesity, GLP-1 drugs dramatically reduced mortality AND suicidal ideation—countering safety fears while demonstrating life-saving benefits

What the researchers found

MACE HR 0.76 (0.72-0.81). MAKE HR 0.64 (0.55-0.74). Mortality HR 0.49 (0.42-0.57). Depression HR 0.63. Suicidal ideation HR 0.42. Substance use HR 0.58. No increased: pancreatitis (HR 1.17 NS), hypoglycemia (HR 1.08 NS), GI symptoms (HR 0.99 NS). 140,169 matched pairs.

Why it matters

This is the largest and most comprehensive study of GLP-1 drugs in non-diabetic obesity. The mental health improvements—58% less suicidal ideation—directly counter safety concerns while demonstrating benefits beyond metabolic outcomes.

How the study worked

Target trial emulation. TriNetX EHR data (July 2021-May 2025). 140,169 matched pairs (280,338 total). Propensity score matching. Cox models. GLP-1RAs vs other AOMs in non-diabetic obesity.

What this study cannot tell us

Observational target trial emulation. Mean follow-up only ~1 year. US EHR data. Cannot fully exclude confounding. Mental health outcomes may reflect healthier baseline in GLP-1 users.

How to read the evidence

Very large target trial emulation from TriNetX. Strong for observational evidence but potential for healthy user bias.

When this study was published

Published in 2025; data July 2021-May 2025.

The bigger picture

This transforms GLP-1 drugs from diabetes/weight loss medications to comprehensive health-improving agents. The mental health benefits are particularly striking and address the most pressing safety concern about these drugs.

Questions still open

Do the mental health benefits persist long-term?
Is the mortality reduction real or driven by healthy user bias?
Should GLP-1 drugs be considered for mental health comorbidities?

Common questions

Are GLP-1 drugs safe for people without diabetes?

This study of 280,338 non-diabetic obese adults provides the strongest safety evidence yet: GLP-1 drugs reduced mortality by 51%, did NOT increase pancreatitis, hypoglycemia, or GI symptoms, and even reduced depression by 37% and suicidal ideation by 58%. This directly counters earlier safety concerns.

Do GLP-1 drugs help mental health?

Remarkably, yes in this study. GLP-1 drug users had 37% less depression, 58% less suicidal ideation/attempts, and 42% less substance use disorder compared to those on other weight loss medications. While this needs confirmation, it suggests GLP-1 drugs may benefit mental health through brain reward pathway modulation.

Read the original research

Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.

Diabetes, obesity & metabolism, 27(11), 6527-6536

View on PubMed ↗Publisher’s paper ↗

Citation

Tang, Huilin; Lu, Yiwen; Zhang, Bingyu; Zhou, Ting; Zhang, Dazheng; Chen, Jiajie; Chen, Yong; Asch, David A; Chen, Yong. (2025). Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.. Diabetes, obesity & metabolism, 27(11), 6527-6536. https://doi.org/10.1111/dom.70054